Jeremy Wyatt is the CEO of ActiGraph, a leading global provider of wearable digital health technology (DHT) solutions for clinical research. With two decades of embedded hardware systems development and related cloud technology expertise, Jeremy has a uniquely well-rounded perspective on the challenges and opportunities of deploying wearable technologies to capture accurate and meaningful patient-centric digital measures. He is considered an industry thought leader and expert in the clinical biosensor space and is a frequent representative and contributor at clinical drug development commercial events, scientific consortiums, and FDA/EMA regulatory meetings. He has an undergraduate degree in electrical engineering from the University of Florida and an MBA from the University of West Florida. Jeremy is a member and contributor to the Digital Medicine (DiMe) Society and participates in various digital biomarker efforts with the Clinical Trial Transformation Initiative (CTTI).

Rachel Humphrey, MD has over 25 years of experience in clinical drug development, particularly in the field of cancer treatments and immunotherapies. Highlights of her career include leading the development of multiple blockbuster cancer therapies: the CTLA-4 inhibiting immunotherapy Yervoy® (ipilimumab) at BMS, the PD-L1 inhibiting immunotherapy Imfinzi® (durvalumab) at AstraZeneca, and the kinase inhibitor cancer drug Nexavar® (sorafenib) at Bayer. After working at these big pharmaceutical companies, Dr Humphrey took her drug development expertise to emerging biotech companies, where she served in the role of Chief Medical Officer at Black Diamond Therapeutics, CytomX Therapeutics and Mirati Therapeutics, respectively. She previously served on the Board of Directors of CytomX Therapeutics and Xilio Therapeutics, respectively, and currently serves on the Board of Directors of Pyxis Therapeutics and Sporos Bioventures. Dr Humphrey started her career as an oncology fellow and staff physician at the National Cancer Institute. She received her training in internal medicine at The Johns Hopkins Hospital, her MD from Case Western Reserve Medical School, and her BA from Harvard University.

Douglas Bryans, PhD is our Founder, President and Chief Executive Officer of Bryllan LLC with responsibility for the operating strategy and overall performance of the company. After a long career with Catalent Pharma Solution, he started Bryllan to support the growing need for clinical and commercial fill finish capacity of a wide range of complex drug/device products. Dr Bryans holds a PhD in Chemistry from the University of Paisley in Glasgow, Scotland and US Patent Number 6,156,339, Process for preparing solid pharmaceutical formulation, approved in 2005.

W. Gregory Sawyer is Chief BioEngineering Officer and Chair of the Department of BioEngineering at the Moffitt Cancer Center in Tampa Florida. Prof. Sawyer has published over 200 journal papers, has over 16,000 citations, holds over 20 patents, and is most proud of his numerous PhD students that are now faculty members and scientists across the globe. He was a member of the original Mars Rover Program (NASA-JPL), a speaker at TED 8, lead the first space-tribology experiments on the International Space Station (ISS), developed novel biomaterials for the ocular surface, and is currently leading efforts in Cancer Engineering.

Michael Ku, PharmD is Vice President of Global Clinical Supply (GCS) within the Medicinal Sciences organization of Pfizer’s Worldwide Research, Development and Medical. Dr Ku has over 25 years of biopharmaceutical experience and currently provides strategic leadership for clinical supply chain functions in support of Pfizer’s clinical trials in over 70 countries. His intellectual curiosity and focus on technology and innovation drive his passion to lead the global clinical supply chain to deliver breakthroughs to patients, especially with the COVID-19 vaccine program.

Prior to joining Pfizer, Dr Ku was the Global Head and Vice President of Clinical Pharmacy Research Services (CPRS) at Genzyme Corporation. He also held several roles of increasing responsibility at Astra Pharmaceuticals (currently AstraZeneca) and Novopharm Limited (currently Teva Canada Limited) in the areas of Clinical Research, Pharmacovigilance, Regulatory Affairs and Quality Assurance.

Having a deep appreciation for talent development and motivated by helping Pfizer colleagues thrive, Dr Ku shares his leadership skills with a focus on diversity and inclusion by serving as the Executive Leader of the Global Asian Alliance Enterprise Colleague Resource Group (GAA ECRG).

Inspired by helping to unleash the potential for pharmacists globally at Pfizer, Dr Ku also serves as an Executive Sponsor for the Pfizer Pharmacy Association (PPA) and founded the Pfizer/MCPHS Biopharmaceutical Fellowship Program as its Program Director and Assistant Professor of Pharmacy Practice at MCPHS University.

Dr Ku currently serves as an Advisor to the Board of Directors of Excir Corporation (www.excir.com) and the International Society of Pharmaceutical Engineers (www.ispe.org). He chairs the Clinical Supply Leadership Forum (CSLF) and is a founding member of the Innovation Outreach Program (IOP). In 2018, he received the prestigious Outstanding 50 Asian Americans in Business Award.

Dr Ku’s educational background includes a Doctor of Pharmacy and Bachelor’s Degree in Pharmacy from MCPHS University as well as a Master’s Degree in Business Administration from Anna Maria College. He also holds a Bachelor of Science Degree in Toxicology from the University of Toronto and is a graduate of the General Management Program from Harvard Business School.

As the Chief Growth Officer for Evinova, Gill Livock leads value- driven growth initiatives and is responsible for the go-to-market strategy for Evinova’s suite of platform solutions which accelerate innovation for Sponsors, CROs and Partners. Evinova is a separate health tech business within the AstraZeneca group offering digital health solutions that are science based, evidence led and human experience driven. Gill has led and been part of digital transformation initiatives within large pharma, driven commercial partnerships within Fortune 100 companies and designed business opportunities to help secure over $500m worth of funding resulting in a double unicorn valuation. During a career that has spanned sponsor and service companies, Gill has developed expertise in digital growth strategies which leverage technology to bridge the gap between patients, sites and study teams.

Kristin Herman is the Executive Director of the Clinical Trials Office (CTO) at the Sidney Kimmel Comprehensive Cancer Center at Jefferson. Herman is responsible for the integration and standardization of all operations, policies, regulations, and finances of the CTO and oversight of all research support personnel. Herman serves a key role in expanding SKCCC clinical trial availability across the Delaware Valley. Prior to joining Jefferson in 2022, Herman spent 5 years at Tallahassee Memorial HealthCare (TMH) in Florida as Director of the Office of Research. There she oversaw the TMH IRB, and clinical research administration across all disease areas. She worked to establish an academic research collaboration with Florida State University, culminating in state funding and approval to develop an FSU academic health center on the TMH campus. She also collaborated closely with the University of Florida to advance population and rural health research via the OneFlorida Clinical Research Consortium where she served on the Executive Committee. Previously, Herman spent 14 years at Memorial Sloan Kettering Cancer Center, working as a clinical research coordinator, and then in operations and project management roles. There she gained experience in clinical trial budget and contract negotiation, research privacy and compliance regulations, and other facets of clinical trials administration. She contributed to the launch of the MSK Cancer Alliance initiative in 2013. Herman has an MBA from FSU, and a BA from the University of Rochester.

Mark Kastantin is the Vice President of Manufacturing Technology at Serán Biosciences. His team blends a creative and fundamentals-based mindset with practical problem solving to develop and scale pharmaceutical processes. Additionally, through internal R&D efforts and partnerships with pharmaceutical companies, he works to translate promising new technologies into practice for clinical manufacturing. His work is guided by expertise in nanoparticle drug delivery systems, colloidal and interfacial phenomena, thermodynamics, and the physical chemistry of proteins, nucleic acids, and polymers.

Prior to joining Serán, Mark worked at Lonza (Capsugel/Bend Research – Bend, OR) on bioavailability enhancement and pulmonary delivery technologies and served as an Assistant Research Professor at the University of Colorado Boulder. Mark holds undergraduate degrees in Brain and Cognitive Sciences and Chemical Engineering from the Massachusetts Institute of Technology and a PhD in Chemical Engineering from the University of California Santa Barbara.

Brad Stefanovic is a seasoned Life Sciences professional with a wealth of experience spanning over 17 years in the domains of Clinical Trial management, clinical technology implementation, vendor management, business operations, development, and strategy. Before joining SLP, he held the esteemed position of Head of Clinical Operations (Vice President) at Ocugen, a pioneering biotech company specializing in gene and cell therapies for Ophthalmology, Orthopedics, and Vaccines. He has also previously held the role of Vice President, Clinical Operations at Aura Biosciences, another prominent biotech firm, where he led a team focused on utilizing Virus Like particles for the treatment of Ocular Oncology and Solid Tumor indications. His leadership extends to various biologics areas, including his role as Senior Director of Clinical Operations and program lead of the Clinical Team for the Injectable Biologics, Orthopedic, Pain Management, and Sports Medicine program at TissueTech Inc. (Now Bio-Tissue), a world-leading Regenerative Medicine company.

His expertise in Life Sciences is the result of his multifaceted career, which encompasses consulting, academic, non-profit, and commercial ventures, including overseeing outsourced full-service clinical trial management activities for large multinational medical companies. Brad is widely recognized as an outstanding scientific communicator in the life sciences industry, with a proven track record of successfully leading large teams through various phases of the medical product lifecycle. His international experience is noteworthy, having relocated from Australia to the USA 10 years ago and effectively managing multiple international clinical programs. In 2022, he earned the prestigious title of alumni of the year at his former institution, the University of the Sunshine Coast, in recognition of his exceptional foresight, strategic engagement, and innovative leadership in the Biotechnology field.

As the SVP Commercial of Beaconcure, Sean is responsible for overseeing all commercial activities within the organization, including Sales, Marketing, and Customer Success. With almost 20 years in business development, including 9 years dedicated to life sciences, Sean brings a wealth of experience to drive growth and customer satisfaction across the Beaconcure organization. Sean has supported organizations of all sizes, from start-ups such as Medable to industry leaders IBM and PPD, a Thermo Fisher company.

Sean has demonstrated a passion for business development and honed his skills in building lasting client and industry relationships. When he’s not advocating for Beaconcure’s solution to transform the clinical trial data validation process, you can find him spending time with his wife and son, on a yoga mat, or rolling around on the floor wrestling his Bernedoodle Eva.

Sean has a Bachelor of Science degree in Biology from the University of North Carolina at Wilmington.